Considerations for the Design and Conduct of a Pharmacovigilance Study Involving Mass Drug Administration in a Resource-Constrained Setting

Open Access

The Policy Platform is for authors to discuss policies that could improve the lives of those at risk of, or affected by, the NTDs.

Demissie Alemayehu,

Affiliation Clinical Affairs, Pfizer, New York, New York, United States of America
⨯
Emma N. Andrews,

Affiliation Clinical Affairs, Pfizer, New York, New York, United States of America
⨯
Paul Glue,

Affiliation Dunedin School of Medicine, Dunedin, New Zealand
⨯
Charles A. Knirsch

* E-mail: Charles.Knirsch@pfizer.com

Affiliation Clinical Affairs, Pfizer, New York, New York, United States of America
⨯

Reader Comments (0)

Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.
Drug interactions
Is the Subject Area "Drug interactions" applicable to this article?

Thanks for your feedback.
Neglected tropical diseases
Is the Subject Area "Neglected tropical diseases" applicable to this article?

Thanks for your feedback.
Drug administration
Is the Subject Area "Drug administration" applicable to this article?

Thanks for your feedback.
Safety studies
Is the Subject Area "Safety studies" applicable to this article?

Thanks for your feedback.
Drug safety
Is the Subject Area "Drug safety" applicable to this article?

Thanks for your feedback.
Statistical data
Is the Subject Area "Statistical data" applicable to this article?

Thanks for your feedback.
Tanzania
Is the Subject Area "Tanzania" applicable to this article?

Thanks for your feedback.